EVAX Key Statistics, Chart & Performance
The current stock price of EVAX is 4.795 USD. In the past month the price decreased by -12.46%. In the past year, price increased by 63.75%.
EVAX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to EVAX. When comparing the yearly performance of all stocks, EVAX is one of the better performing stocks in the market, outperforming 80.35% of all stocks.
EVAX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EVAX. EVAX has a bad profitability rating. Also its financial health evaluation is rather negative.
EVAX Financial Highlights
Over the last trailing twelve months EVAX reported a non-GAAP Earnings per Share(EPS) of -4.01. The EPS increased by 45.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.35% | ||
| ROE | -192.35% | ||
| Debt/Equity | 1.73 |
EVAX Forecast & Estimates
9 analysts have analysed EVAX and the average price target is 12.58 USD. This implies a price increase of 162.36% is expected in the next year compared to the current price of 4.795.
For the next year, analysts expect an EPS growth of 85.61% and a revenue growth 14.66% for EVAX
EVAX Ownership
EVAX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.93 | 382.98B | ||
| AMGN | AMGEN INC | 15.08 | 177.57B | ||
| GILD | GILEAD SCIENCES INC | 14.86 | 151.03B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.17 | 110.85B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 77.93B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 703.11 | 47.37B | ||
| INSM | INSMED INC | N/A | 33.92B | ||
| NTRA | NATERA INC | N/A | 33.40B | ||
| BIIB | BIOGEN INC | 10.06 | 24.70B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.87B | ||
| INCY | INCYTE CORP | 16.37 | 20.63B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.87 | 20.31B |
Related stock screener links
About EVAX
Company Profile
Evaxion AS engages in the discovery and development of immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Company Info
EVAXION A/S
Dr. Neergaards Vej 5F
Hoersholm 1260 DK
CEO: Lars Staal Webner
Employees: 46
EVAXION A/S / EVAX FAQ
Can you describe the business of EVAXION A/S?
Evaxion AS engages in the discovery and development of immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Can you provide the latest stock price for EVAXION A/S?
The current stock price of EVAX is 4.795 USD. The price decreased by -5.24% in the last trading session.
Does EVAXION A/S pay dividends?
EVAX does not pay a dividend.
How is the ChartMill rating for EVAXION A/S?
EVAX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of EVAXION A/S (EVAX) based on its PE ratio?
EVAXION A/S (EVAX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.01).
What is the expected growth for EVAX stock?
The Revenue of EVAXION A/S (EVAX) is expected to grow by 14.66% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is EVAXION A/S worth?
EVAXION A/S (EVAX) has a market capitalization of 38.00M USD. This makes EVAX a Nano Cap stock.